If you have any questions regarding diagnosis or management, please refer to the NMOSD service. If the test is positive, please refer the patient into one of the NMOSD centres. If another obvious and definite diagnosis is present.Unexplained ‘encephalitis’ and seizures with brain lesions.‘Atypical MS’ or other uncharacterized CNS demyelination With the development of sensitive and specific cell-based assays, the detection of IgG antibodies targeting conformationally preserved full-length human myelin-oligodendrocyte glycoprotein (MOG) has differentiated anti-MOG antibody-associated disease (MOGAD) from other demyelinating disorders.Recurrent, bilateral or severe optic neuritis Longitudinal or recurrent transverse myelitis.azathioprine) may need to be used much like we treat AQP4 antibody associated NMOSD. If a relapse occurs then additional immunosuppressants (e.g. what is the risk of disability? Does the disease go into spontaneous remission?) Treatment usually consists of a slow taper of corticosteroids (prednisolone) over 6 months to a year after the first event. Since we are not sure about the natural course of the disease (e.g. optic neuritis) and MOG antibodies often have a ‘one-off’ event and usually recover well from their illness Treatment of MOG antibody associated disease Recent, though preliminar y, reports suggest that MOG-EM and NMDAR en. This report describes two patients with MOG-IgG positive OPN. Additi onal testing for NMDAR antibodies is highly rec ommended in patients with teratoma and neurological symptoms 60. Since she has been relapsed free, she is being observed without treatment. testing for both Aquaporin 4 (AQP4) Antibodies and Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies is strongly recommended for new cases of NMOSD. In contrast to typical NMOSD (caused by AQP4 antibodies) up to half of the persons with an episode of demyelination (e.g. Repeat MOG antibody testing performed 11 months after initial testing showed persistently positive titres at 1:40. Patients were included if they had an acquired demyelinating syndrome lasting 24 hours or more, had a positive MOG antibody test and had six months or more of follow-up. Neuromyelitis optica (NMO) and Myelin Oligodendrocyte Glycoprotein (MOG) are both tests for the eyes. MOG antibodies are found on the myelin sheath rather than the astrocyte as in AQP4 antibodies and cause damage to the myelin. Patients were drawn from all tertiary hospitals in France between 2014, when testing for MOG antibodies began, and 2019. However, their discovery is recent and there is much to be learned. MOG antibodies have recently been reported in some people who have transverse myelitis and/or optic neuritis and/or ADEM (acute disseminated encephalomyelitis) and AQP4 antibody negative NMOSD. MOG stands for Myelin Oligodendrocyte Glycoprotein. MOG antibodies MOG antibody associated demyelination and NMOSD

Mog antibody testing